<DOC>
	<DOCNO>NCT01092130</DOCNO>
	<brief_summary>The renin-angiotensin system ( RAS ) regulatory system play essential role patient chronic heart failure ( CHF ) . Plasma renin activity ( PRA ) strong independent predictor outcome , also presence ACE inhibitor ( ACE-i ) and/or angiotensin receptor blocker ( ARBs ) . Recently , show vitamin D regulate renin transcription activate vitamin D receptor ( VDR ) . Thus , specific activation VDR represent novel target therapeutic intervention CHF . Currently , clinical data lacking . The investigator aim investigate effect administration vitamin D patient CHF .</brief_summary>
	<brief_title>Study Investigate Effects Vitamin D Administration Plasma Renin Activity Patients With Stable Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Out clinical patient â‰¥ 18 year age , male female . Patients diagnosis chronic heart failure ( NYHA Class II , III IV ) . Patients must least treated ACEi stable dose ( least enalapril 10 mg daily ACEi , e.g . ramipril , quinapril , lisinopril , fosinopril , perindopril , trandolapril ; equivalent dos , maximum tolerate dose ) intolerant ACEi ARB therapy ( Candesartan 8 mg daily ARB equivalent dose , maximum tolerate dose ) least 4 week prior visit 1 . Patients must treat beta blocker unless contraindicate tolerate stable dose least 4 week prior visit 1 ( patient target dose absence medication , reason document ) . Concomitant use ACEi and/or ARB and/or aldosterone antagonist permit . LVEF &gt; 45 % visit 1 ( local measurement , measure within past 12 month assess echocardiogram , MUGA ventricular angiography ) . History hypersensitivity study drug . Patients phenylketonuria . Patients fructose intolerance . Current acute decompensated heart failure . Hypercalcemia ( &gt; 2.65 mmol/l , correct albumin ) . Hypercalciuria . Estimated glomerular filtration fraction ( eGFR ) 30 60 ml/min/1.73m2 measure modified diet renal disease ( MDRD ) formula . Nephrolithiasis . Sarcoidosis . Use follow medication : corticosteroid , thyroxin , anti epileptic drug , tetracycline , quinolones Intake supplement contain vitamin D and/or calcium . Acute coronary syndrome , stroke , transient ischemic attack , cardiac , carotid major vascular surgery , percutaneous coronary intervention ( PCI ) carotid angioplasty , within past 3 month . Coronary carotid artery disease likely require surgical PCI . Right heart failure due severe pulmonary disease . Diagnosis peripartum chemotherapy induce cardiomyopathy within last year . Patients history heart transplant transplant list LVAD device ( left ventricular assistance device ) . Documented ventricular arrhythmia syncopal episode within past 3 month untreated . Documented history ventricular tachycardia ventricular fibrillation without ICD ( internal cardiac defibrillator ) . Symptomatic bradycardia , second third degree heart block without pacemaker . Implantation CRT ( cardiac resynchronization therapy ) device within prior 3 month . Presence hemodynamically significant mitral /or aortic valve disease , except mitral regurgitation secondary leave ventricular dilatation . Presence hemodynamically significant obstructive lesion leave ventricular outflow tract , include aortic stenosis . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug . Any history pancreatic injury , pancreatitis evidence impair pancreatic function/injury indicate abnormal lipase amylase . Primary liver disease consider life threaten . Currently active gastritis , duodenal gastric ulcer , gastrointestinal/rectal bleed 3 month prior Visit 1 . History presence disease ( i.e . include malignancy ) life expectancy &lt; 5 year . Current doubleblind treatment heart failure ( HF ) trial . Participation investigational drug study time enrollment within past 30 day 5 half life enrollment whichever longer . Any surgical medical condition opinion investigator medical monitor would jeopardize evaluation efficacy safety . History noncompliance medical regimen patient consider potentially unreliable . Pregnant lactating woman . Treatment follow drug within past 4 week prior Visit 1 ( T0 ) : Direct renin inhibition include Aliskiren Intravenous vasodilator and/or inotropic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Plasma renin activity</keyword>
	<keyword>Renin angiotensin system</keyword>
</DOC>